Trav8-2: A Protein Involved in The Immune Response and Potential Drug Target

Target Name: TRAV8-2

NCBI ID: G28684

TRAV8-2

Other Name(s): TCRAV8S2 | TCRAV1S5 | TRAV82 | T cell receptor alpha variable 8-2

Trav8-2: A Protein Involved in The Immune Response and Potential Drug Target

Trav8-2 (TCRAV8S2) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the T cell receptor alpha chain, which is a family of proteins that play a critical role in the immune system.

One of the interesting aspects of Trav8-2 is its function in the immune response. Trav8-2 is involved in the regulation of T cell responses to infection, and it has been shown to play a key role in the development of autoimmune diseases. In addition, Trav8-2 has also been shown to play a role in the regulation of inflammation, which is a critical aspect of the immune response.

Another interesting aspect of Trav8-2 is its potential as a drug target. Trav8-2 has been shown to interact with a variety of molecules, including inhibitors of the immune response and molecules involved in inflammation. This makes it an attractive target for researchers and pharmaceutical companies looking for new treatments for a range of diseases.

In addition to its potential as a drug target, Trav8-2 also has a number of potential applications in basic research. For example, Trav8-2 has been shown to play a role in the regulation of cell survival and division, which is an important aspect of many diseases. Additionally, Trav8-2 has also been shown to play a role in the regulation of cell signaling pathways, which is important for the development of many diseases.

Overall, Trav8-2 is a protein that has a number of potential applications in both basic and clinical research. Its involvement in the regulation of the immune system and its potential as a drug target make it an attractive target for further investigation. Further studies are needed to fully understand its role in the immune response and its potential as a therapeutic agent.

Protein Name: T Cell Receptor Alpha Variable 8-2

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV8-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV8-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets